Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Daniel J. George, Theodore F. Logan, Robert Jones, Andrew B. Nixon, Lisa Pickering, Joel Picus, Ulka N. Vaishampayan, Christian K. Kollmannsberger, Qian Yang, Christopher W. Ryan, Jorge A. Garcia, Andrew Protheroe, Andrea Carmack, Susan Halabi, Andrew J. Armstrong, Walter M. Stadler, Robert E. Hawkins, Igor Puzanov, John D. Hainsworth, Tim Eisen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(12)
Purpose: Biomarkers are needed in patients with non–clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines in the context of a randomi
Autor:
Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Vincent Ribrag, Charles Herbaux, Walter J. Urba, Yoshinobu Koguchi, John M. Timmerman, Caron A. Jacobson, Satyendra Suryawanshi, John E. Godwin, Ronald Levy, Roch Houot, Andrew D. Zelenetz, Cecilia Carpio, Deanne Lathers, Gilles Salles, Jaclyn Neely, Yali Liu, Radhakrishnan Ramchandren
Publikováno v:
Scientia
American Journal of Hematology
American Journal of Hematology, Wiley, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
American Journal of Hematology, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
American Journal of Hematology
American Journal of Hematology, Wiley, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
American Journal of Hematology, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Limfoma de cèl·lules B; Urelumab Linfoma de células B; Urelumab B-cell lymphoma; Urelumab Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29dadecdd66de9605b92ac4df56b311
https://hdl.handle.net/11351/6523
https://hdl.handle.net/11351/6523
Autor:
Shilpa Gupta, Monika Joshi, James K. Schwarz, Joshua M. Lang, Arkadiusz Z. Dudek, Ajjai Alva, Yousef Zakharia, Li C Liu, Anas Al-Janadi, Eric A. Singer, Theodore F. Logan
Publikováno v:
Journal of Clinical Oncology
PURPOSE We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS Patients with metas
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Robert S. Alter, J. Thaddeus Beck, Monika Joshi, Earle F. Burgess, David R. Shaffer, Mayer Fishman, Ralph J. Hauke, Nicholas J. Vogelzang, Martin H. Voss, Nauman Moazzam, Xiaosha Zhang, Chad E. Glasser, Elizabeth R. Plimack, Rupal S. Bhatt, Michael B. Atkins, Theodore F. Logan, Rahul A. Parikh, Matthew L. Sherman, Brian I. Rini
Publikováno v:
Cancer
BACKGROUND In a prior open-label study, the combination of dalantercept, a novel antiangiogenic targeting activin receptor-like kinase 1 (ALK1), plus axitinib was deemed safe and tolerable with a promising efficacy signal in patients with advanced re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0196483f823f2190dadaf46fe5ecb04c
https://europepmc.org/articles/PMC6602847/
https://europepmc.org/articles/PMC6602847/
Autor:
Joel Picus, Robert Jones, Susan Halabi, Samuel Broderick, Daniel J. George, Sadie Oberg, Andrew J. Armstrong, Christine M. Lusk, John D. Hainsworth, Ulka N. Vaishampayan, Jorge A. Garcia, Christopher W. Ryan, Theodore F. Logan, Tim Eisen, Walter M. Stadler, Robert E. Hawkins, Igor Puzanov, Lisa Pickering, Andrew Protheroe, Christian K. Kollmannsberger
Publikováno v:
The Lancet Oncology. 17:378-388
Summary Background Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF
Autor:
Theodore F. Logan, Lee D. Cranmer, Jatinder Singh, Sanjiv S. Agarwala, Bret Taback, Theresa L. Luna, Christopher D. Lao, Marc S. Ernstoff, Sandra Aung, Lawrence E. Flaherty, Jose Lutzky, Brendan D. Curti, David H. Lawson, Joseph I. Clark
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients w
Autor:
Howard L. Kaufman, David F. McDermott, Jatinder Singh, Janice P. Dutcher, Meenu Kaur, Michael K.K. Wong, Nancy C. Gregory, Gregory A. Daniels, Theresa L. Luna, Brendan D. Curti, Joseph I. Clark, Michael A. Morse, Theodore F. Logan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Background Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE
Autor:
Terrence M. Katona, Justin D. Richey, Amanda J. Malek, Simon Warren, Liang Cheng, Theodore F. Logan, Kristin M. Post, Joshua R. Bradish, Joyashree D. Sen, Leslie A. Fecher, Kari Meehan
Publikováno v:
Modern Pathology. 28:480-486
Systemic targeted molecular therapy, in the form of a selective BRAF inhibitor with or without a MEK inhibitor, is a standard treatment for patients with BRAF V600 mutation-positive melanoma with unresectable stage III and IV disease. Patients with B
Autor:
Karl D. Lewis, Thomas Olencki, Thomas W. Flaig, Anthony Jarkowski, Dexiang Gao, Bruce G. Redman, Theodore F. Logan, Marcus Bolden, Elaine T. Lam, Neeraj Agarwal, Timothy M. Kuzel, Arun Sendilnathan, Paul Monk, Jamie Poust, Michael K.K. Wong
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Although tyrosine kinase inhibitors (TKI) are the most common first-line therapy for metastatic renal cell carcinoma, high-dose interleukin-2 (HD-IL2) remains the only agent that provides durable complete responses. The optimal sequence of these agen